Drug Master File—Electronic Submission through eCTD: An Overview

Authors

  • Y. Patel Graduate School of Pharmacy- Gujarat Technological University
  • A. Pathan

DOI:

https://doi.org/10.37591/tdd.v6i1.447

Abstract

A Drug Master File (DMF) is a supporting document for various applications such as Investigational New Drug Application (IND), New Drug Application (NDA), Abbreviated New Drug Application (ANDA), Biologic License Application (BLA), etc. Mainly product’s chemistry, manufacturing, and control (CMC) part is covered in the DMF. As per the current guidelines of US Food & Drug Administration (USFDA), all types of DMFs are mandatory to be submitted through Electronic Common Technical Document (eCTD) only, except for Type III DMFs for which date is extended to May 5, 2020. For the electronic submission of DMFs, there are few steps needed to be completed such as obtaining the pre-assigned application number, converting DMF to eCTD format, setting up an Electronic Submission Gateway (ESG) account, and submission through ESG to the FDA. Electronic submission using eCTD makes submission and review by the FDA both easy, though there are many mistakes done by the submitter which leads to rejection of the electronic submission. The FDA has made available all the required guidance documents for setting up an ESG account and submission through eCTD so that the number of rejections of submission can be reduced.

 

Keywords: drug master file (DMF), electronic submission, eCTD, master file


Cite this Article

Y.Patel, A.Pathan. Drug Master File—Electronic Submission through eCTD: An Overview. Trends in Drug Delivery. 2019; 6(1): 8–13p.


 

 

Downloads

Published

2019-05-03

Issue

Vol. 6 No. 1 (2019)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.